selected publications
-
academic article
-
Drug response prediction in high-risk multiple myeloma.
Gene.
644.
2018
Dual inhibition of DNMTs and EZH2 can overcome both intrinsic and acquired resistance of myeloma cells to IMiDs in a cereblon‐independent manner.
Molecular Oncology.
12.
2018
Early relapsed disease of multiple myeloma following up-front HDM-ASCT: a study based on the Danish Multiple Myeloma Registry in the period 2005 to 2014.
Leukemia.
32.
2018
Lenalidomide versus lenalidomide + dexamethasone prolonged treatment after second‐line lenalidomide + dexamethasone induction in multiple myeloma.
Cancer Medicine.
7.
2018
Risk factors for blood stream infections in multiple myeloma: A population‐based study of 1154 patients in Denmark.
European Journal Of Haematology.
101.
2018
Causes of early death in multiple myeloma patients treated with high‐dose therapy followed by autologous stem cell transplantation: A study based on the nationwide Danish Multiple Myeloma Registry.
American Journal of Hematology.
92.
2017
Drug Response Prediction in High Risk Multiple Myeloma.
Clinical Lymphoma Myeloma & Leukemia.
17.
2017
Immunoparesis in newly diagnosed Multiple Myeloma patients: Effects on overall survival and progression free survival in the Danish population.
PLoS ONE.
12.
2017
Impact of prior therapy on the efficacy and safety of oral ixazomib-lenalidomide-dexamethasone vs. placebo-lenalidomide-dexamethasone in patients with relapsed/refractory multiple myeloma in TOURMALINE-MM1..
Haematologica.
102.
2017
The impact of comorbidity on mortality in multiple myeloma: a Danish nationwide population‐based study.
Cancer Medicine.
6.
2017
134P APO010 sensitivity in relapsed multiple myeloma patients.
Annals of Oncology.
27.
2016
Cereblon Is Downregulated By Promoter Nucleosome Occupancy in Acquired IMiD Resistance: The Potential of IMiD Resensitization By Epigenetic Therapy.
Blood.
128.
2016
Gene expression risk signatures maintain prognostic power in multiple myeloma despite microarray probe set translation.
International Journal of Laboratory Hematology.
38.
2016
Impact of prior therapy on efficacy and safety of oral ixazomib-lenalidomide-dexamethasone (IRd) vs placebo-Rd in patients (pts) with relapsed/refractory multiple myeloma (RRMM) in TOURMALINE-MM1..
Journal of Clinical Oncology.
34.
2016
Phase 1/2 study of daratumumab, lenalidomide, and dexamethasone for relapsed multiple myeloma.
Blood.
128.
2016
Smoldering multiple myeloma risk factors for progression: a Danish population‐based cohort study.
European Journal Of Haematology.
97.
2016
The Danish National Multiple Myeloma Registry.
Clinical Epidemiology.
Volume 8.
2016
A Phase I Dose-Escalation Study of Antibody BI-505 in Relapsed/Refractory Multiple Myeloma.
Clinical Cancer Research.
21.
2015
American Society of Blood and Marrow Transplantation, European Society of Blood and Marrow Transplantation, Blood and Marrow Transplant Clinical Trials Network, and International Myeloma Working Group Consensus Conference on Salvage Hematopoietic Cell Transplantation in Patients with Relapsed Multiple Myeloma.
Biology of Blood and Marrow Transplantation.
21.
2015
Causes of early death in multiple myeloma patients who are ineligible for high‐dose therapy with hematopoietic stem cell support: A study based on the nationwide Danish Myeloma Database.
American Journal of Hematology.
90.
2015
Characteristics and Long-Term Outcome of Patients with Systemic Immunoglobulin Light-Chain Amyloidosis.
Acta Haematologica.
133.
2015
Continued improvement in overall survival in elderly multiple myeloma patients after 2008; a population based study from the Danish Multiple Myeloma Registry.
Clinical Lymphoma Myeloma & Leukemia.
15.
2015
Daratumumab in Combination with Lenalidomide and Dexamethasone in Patients with Relapsed or Relapsed and Refractory Multiple Myeloma: Updated Results of a Phase 1/2 Study (GEN503).
Blood.
126.
2015
Does Low-Molecular-Weight Heparin Influence the Antimyeloma Effects of Thalidomide? A Retrospective Analysis of Data from the GIMEMA, Nordic and Turkish Myeloma Study Groups.
Acta Haematologica.
133.
2015
Growth differentiation factor 15 (GDF15) promotes osteoclast differentiation and inhibits osteoblast differentiation and high serum GDF15 levels are associated with multiple myeloma bone disease.
Haematologica.
100.
2015
Ixazomib, an Investigational Oral Proteasome Inhibitor (PI), in Combination with Lenalidomide and Dexamethasone (IRd), Significantly Extends Progression-Free Survival (PFS) for Patients (Pts) with Relapsed and/or Refractory Multiple Myeloma (RRMM): The Phase 3 Tourmaline-MM1 Study (NCT01564537).
Blood.
126.
2015
N-terminal pro-C-type natriuretic peptide in serum associated with bone destruction in patients with multiple myeloma.
Biomarkers in Medicine.
9.
2015
Polymorphisms in the heparanase gene in multiple myeloma association with bone morbidity and survival.
European Journal Of Haematology.
94.
2015
Salvage bortezomib–dexamethasone and high-dose melphalan (HDM) and autologous stem cell support (ASCT) in myeloma patients at first relapse after HDM with ASCT. A phase-2 trial.
Bone Marrow Transplantation.
50.
2015
Serum YKL-40: a new independent prognostic marker for skeletal complications in patients with multiple myeloma.
Leukemia & Lymphoma.
56.
2015
Targeting CD38 with Daratumumab Monotherapy in Multiple Myeloma.
New England Journal of Medicine.
373.
2015
The Rev II Trial: Lenalidomide and Dexamethasone As Second Line Treatment in Myeloma Followed By Extended Lenalidomid Vs Len/Dex.
Blood.
126.
2015
Bortezomib, melphalan, prednisone (VMP) versus melphalan, prednisone, thalidomide (MPT) in elderly newly diagnosed multiple myeloma patients: A retrospective case‐matched study.
American Journal of Hematology.
89.
2014
Dose-dependent efficacy of daratumumab (DARA) as monotherapy in patients with relapsed or refractory multiple myeloma (RR MM)..
Journal of Clinical Oncology.
32.
2014
Genetic variants in the P2RX7 gene are associated with risk of multiple myeloma.
European Journal Of Haematology.
93.
2014
Panobinostat plus bortezomib and dexamethasone versus placebo plus bortezomib and dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma: a multicentre, randomised, double-blind phase 3 trial.
The Lancet Oncology.
15.
2014
Safety and Efficacy of Daratumumab with Lenalidomide and Dexamethasone in Relapsed or Relapsed, Refractory Multiple Myeloma.
Blood.
124.
2014
Safety and efficacy of daratumumab with lenalidomide and dexamethasone in relapsed or relapsed, refractory multiple myeloma..
Journal of Clinical Oncology.
32.
2014
The role of epigenetics in the biology of multiple myeloma.
Blood Cancer Journal.
4.
2014
-
dataset
-
Baseline characteristics for the entire cohort..
public-library-of-science.
2017
Immunoparesis and association to OS and PFS in different age groups..
public-library-of-science.
2017
Immunoparesis in newly diagnosed Multiple Myeloma patients: Effects on overall survival and progression free survival in the Danish population.
public-library-of-science.
2017
Multivariable analysis of both qualitative and quantitative immunoparesis as risk factors for OS and PFS in all patients..
public-library-of-science.
2017
Multivariable analysis of factors for OS..
public-library-of-science.
2017
Multivariable analysis of factors for PFS..
public-library-of-science.
2017
-
hide from search
-
Aberrant microRNA expression in multiple myeloma.
European Journal Of Haematology.
2013
Bortezomib consolidation after autologous stem cell transplantation in multiple myeloma: a Nordic Myeloma Study Group randomized phase 3 trial.
Blood.
2013